Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …

Purpose A prior study demonstrated that addition of continuous daily erlotinib fails to
improve response rate or survival in non–small-cell lung cancer (NSCLC) patients treated …

Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …

Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

LBA8005 Background: Second-line therapy for advanced NSCLC patients (pts) after
progression on platinum-based regimens typically employs CT or E. Improved PFS in E …

P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with
advanced non-small cell lung cancer following failure of platinum-based chemotherapy × …

Background Combined inhibition of vascular, platelet-derived, and epidermal growth factor
receptor (EGFR) pathways may overcome refractoriness to single agents in platinum …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …